Theralase Technologies Inc. V.TLT

Not sure if TLT can attack this gene

[O12009]

AstraZeneca and Daiichi Sankyo on Friday revealed new study results supporting their revised approval plans for the closely watched cancer drug datopotamab deruxtecan, or dato-dxd. A pooled analysis from two clinical trials showed dato-dxd kept tumors in check for a median of about six months in people whose non-small cell lung tumors were driven to growth by mutations in the EGFR gene. Among 117 people, median survival was 15.6 months, according to a statement. The findings underpin an accelerated approval filing the partners submitted last month in EGFR-mutated lung cancer — a much narrower request than they’d originally anticipated. 

If TLT can cure this we are headed to infinity and beyond.

[DJDawg]

That is the great thing about Rutherrin. It is tumour agnostic and mutation agnostic. Cancer cannot grow withour iron As a result, no matter the cancer type or mutation, they have increased expression of the iron uptake receptor (that grabs iron from outside the cell) call transferrin receptor Rutherrin gets in via the transferrin receptor which spares normal cells, relatively. Once inside

[O12009]

Thanks Dawg that makes me very happy moving forward.

[3Crows]

I see 7 "likes" to this post. Mine will be the 8th. I'm wondering how many of us actually understood any of it but boy, does it ever sound like good news for us as investors in this cancer fighting drug! 

[BlueFranky]

I'm with you on that 3Crows.. A little over my pay grade, I'm afraid .. but I get the gist. Dawg... That is one snappy tune.. especially that rather puquant morsel about our little darling being "the future of oncology" Like being on the precipice of experiencing something that has never been. In the immortal words of Hunter S Thompson: "The edge - The only ones who know

[DJDawg]

I once looked up an article about how different transferrin expression is between cancer and non-cancer. Check out this image. The dark brown represent increased expression of the exact receptor that rutherrin uses to trojan horse its way into cells. So in the pictures you can see where the rutherrin molecule would home in on and enter. https://ibb.co/sFF89mg Note that brain cancer has crazy

[Oden6570]

Theralase® Demonstrates Unique Ability to Activate Rutherrin® with Diabetes Drug Toronto, Ontario –August 21 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation-activated small molecules for the safe and effective